Loading organizations...
§ Private Profile · Headington, Oxfordshire, United Kingdom
Biotechnology company developing novel monoclonal antibodies for chronic inflammatory diseases, utilizing the HEPTAD platform for GPCR targets.
DJS Antibodies is a biotechnology company based in Oxford, United Kingdom, that researches and develops novel monoclonal antibodies targeting chronic inflammatory diseases such as severe rheumatoid arthritis. The organization utilizes its proprietary HEPTAD platform to discover therapeutic antibodies for historically difficult transmembrane protein targets, specifically focusing on complex G protein coupled receptors. Prior to its strategic exit, the enterprise raised approximately $8 million in initial early stage venture funding and grants from a syndicate of prominent life science investors including Oxford Science Enterprises, Johnson & Johnson Innovation, LifeArc, and Amgen Ventures. In October 2022, the multinational pharmaceutical corporation AbbVie Inc. fully acquired the business for a purchase price of $255 million in cash to integrate the HEPTAD technology and expand its broader immunology therapeutics portfolio. DJS Antibodies was originally founded in 2014 by David Llewellyn and Joe Illingworth.
DJS Antibodies has raised $8.0M across 1 funding round.
DJS Antibodies has raised $8.0M in total across 1 funding round.
DJS Antibodies has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Seed in December 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 22, 2020 | $8M Seed | David Holbrook, Sedgwick Yard | Amgen Ventures, Oxford Science Enterprises | Announced |
DJS Antibodies has raised $8.0M in total across 1 funding round.
DJS Antibodies's investors include David Holbrook, Sedgwick Yard, Amgen Ventures, Oxford Science Enterprises.